MAPT and prostate cancer: For example, estramustine-resistant DU145 and docetaxel-resistant PC3 and DU145 prostate cancer cell lines showed higher levels of tau expression compared with their respective parental cell lines [60,61] and knocking down tau in PC3, and DU145 cells increased sensitivity to docetaxel in both parental and docetaxel-resistant cell lines, but the effect was more significant in the docetaxel-resistant cells [61].